Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mixture containing mix interferon-alpha hypotype

A technology of interferon α and mixture, which is applied in the field of mixture containing mixed interferon-α subtypes, which can solve the problems of large side effects

Inactive Publication Date: 2008-08-20
CYTOPHARM
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Sometimes these side effects caused by large doses are greater than the impact of the disease itself

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mixture containing mix interferon-alpha hypotype
  • Mixture containing mix interferon-alpha hypotype
  • Mixture containing mix interferon-alpha hypotype

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 6

[0042] Example 6 utilizes the effect of human epithelial cells (WISH) against encephalomyocarditis virus (EMCV) to describe the antiviral activity of IFN-α in individual or specific ratio subtypes (subtype). The interferon unit in this measurement process is The 50% end point was defined as the reciprocal dilution adjusted to the NIH reference standard (Gallium 23-902-532). The antiviral specific activity of IFN-α ranged from 92 to 1268 MIU / mgIFN. The amount of IFN-α was obtained using a commercial enzyme Linked immunosorbent assay (ELISA) (PBL, USA) measured. IFN-α8 has a relatively high antiviral activity in the ratio of 1:1 molar molecular weight, about 618MIU / mg IFN, which has been proved to be consistent with that in this Compared with other components in the invention process. The above composition has higher antiviral activity compared with the commercial IFN-α2 product, Roferon A, as described in Example 6.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an IFN-Alpha subtype compound generated by lymphoblast, which is characterized in that the rarefied IFN-Alpha compound has higher specific activity, and can be used to cure cancer, virus and immunity diseases.

Description

technical field [0001] The present invention relates to an isolated protein composition, the mixture being human interferon-alpha produced by human lymphoblastoid cells. Background technique [0002] There are three main types of human interferon, namely interferon-α, interferon-β and interferon-γ. Among these subtypes, interferon-α is considered to be the most effective in the treatment of cancer. Human interferon-α is composed of at least 13 genes located on human chromosome 9. There is 78% to 95% amino acid similarity between the subtypes of interferon-α (Henco, et al., 1985; Diaz, et al., 1996). Some of the interferon-alpha proteins have the functions of anti-virus, anti-growth and immune regulation. For example, 11 IFN-α subtypes were isolated from the culture medium of lymphocytes stimulated with Sendai virus. Each interferon-α protein is composed of 165 or 166 amino acids, and its molecular weight ranges from 18 to 27 kilodaltons (kDa), depending on the degree of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/21A61K9/00A61K9/06A61K9/08A61K9/10A61K9/107A61K9/14A61K9/72A61P31/12C12N5/08
Inventor 林富勇黄雪莉杨志平李清源
Owner CYTOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com